Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
| Product: | Prevymis |
| Active Ingredient: | Letermovir 240mg/12mL |
| Dosage Form: | Concentrate for infusion |
| New Zealand Sponsor: | Merck Sharp & Dohme (New Zealand) Limited |
| Manufacturer: | MSD International GmbH, t/a MSD Ireland (Carlow), Carlow, Ireland |
| Product: | Prevymis |
| Active Ingredient: | Letermovir 480mg/24mL |
| Dosage Form: | Concentrate for infusion |
| New Zealand Sponsor: | Merck Sharp & Dohme (New Zealand) Limited |
| Manufacturer: | MSD International GmbH, t/a MSD Ireland (Carlow), Carlow, Ireland |
| Product: | Prevymis |
| Active Ingredient: | Letermovir 240mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Merck Sharp & Dohme (New Zealand) Limited |
| Manufacturer: | MSD International GmbH, t/a MSD Ireland (Ballydine), Kilsheelan, Ireland |
| Product: | Prevymis |
| Active Ingredient: | Letermovir 480mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Merck Sharp & Dohme (New Zealand) Limited |
| Manufacturer: | MSD International GmbH, t/a MSD Ireland (Ballydine), Kilsheelan, Ireland |
| Product: | Skyrizi |
| Active Ingredient: | Risankizumab 75mg/0.83mL |
| Dosage Form: | Solution for injection |
| New Zealand Sponsor: | AbbVie Limited |
| Manufacturer: | Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany |
Dated this 18th day of September 2020.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).